Fig. 3

B02 significantly enhanced cytotoxicity of cisplatin in both OECM1 EV cells and RAD51 OE cells. (A) XTT assay in OECM1 EV and OECM1 RAD51 OE cells at 48 h after B02 treatment. B02 decreased cell viability both in control and RAD51 OE cells, (B) XTT assay in OECM1 EV and OECM1 RAD51 OE cells at 72 h after B02 treatment, (C) XTT assay in OECM1 EV cells at 48 h after cisplatin treatment with/without B02 and B02 enhanced cytotoxicity of cisplatin, (D) XTT assay in OECM1 EV cells at 72 h after cisplatin treatment with/without B02 and B02 enhanced cytotoxicity of cisplatin, (E) XTT assay in OECM1 RAD51 OE cells at 48 h after cisplatin treatment with/without B02 and B02 enhanced cytotoxicity of cisplatin, (F) XTT assay in OECM1 RAD51 OE cells at 72 h after cisplatin treatment with/without B02 and B02 enhanced cytotoxicity of cisplatin

OECM1 EV, control; OECM1 RAD51 OE, overexpression; *, P < 0.05; **, P < 0.01; ***, P < 0.001